Patients who survive a first stroke are often left with permanent disabilities, and have significant needs for rehabilitation and long-term care. Antihypertensive treatment reduces the risk of cardiovascular events such as stroke. The purpose of this study was to investigate the cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke. The cost-effectiveness analysis was based on data from Study on COgnition and Prognosis in the Elderly (SCOPE), where patients were randomly assigned to receive the angiotensin receptor blocker candesartan or placebo, with open-label active antihypertensive treatment added as needed. The analysis was carried out using a Markov model, which combined clinical and resource utilization data from SCOPE with Swedish retail prices for drugs and unit costs for inpatient stays, and outpatient visits. The cost per patient was 1949 EUR in the candesartan group and 1578 EUR in the control group. The largest share of the cost was attributed to antihypertensive treatment in the candesartan group and to the long-term cost of stroke in the control group. Candesartan-based antihypertensive treatment was associated with 0.0289 additional quality-adjusted life-years (QALYs) per patient and an incremental cost per QALY gained of approximately 13 000 EUR. Sensitivity analyses showed that these results were fairly stable. In conclusion, the cost per QALY gained with candesartan-based antihypertensive treatment lies within the range of society's willingness to pay for health gains. The results indicate that candesartan-based antihypertensive treatment is costeffective for the prevention of nonfatal stroke.
Introduction
Stroke is the third most common cause of death in the Western world, after cardiac disease and cancer. 1, 2 It is also an important cause of morbidity, since a majority of patients survive their first stroke. About one half of the survivors are left with permanent disabilities, and have significant needs for rehabilitation and long-term care. Morbidity and mortality from cardiovascular disease are thus high and are believed to increase in the future, due to an ageing population. 3, 4 As a result of the high morbidity, cardiovascular disease is associated with high costs, 5, 6 which makes prevention potentially valuable.
Hypertension is an established risk factor for stroke and coronary heart disease. [7] [8] [9] Antihypertensive treatment reduces the risk of cardiovascular disease in the middle-aged and elderly with moderate to high blood pressure, [10] [11] [12] and has also been found to be cost-effective in that population. [13] [14] [15] The evidence of the benefit from antihypertensive treatment in elderly patients with mildly elevated blood pressure is, however, less clear.
Study on COgnition and Prognosis in the Elderly (SCOPE) was initiated as a placebo-controlled study with the aim of assessing the effects of antihypertensive treatment with the angiotensin II type 1 (AT 1 ) receptor blocker candesartan cilexetil (candesartan) in elderly patients (70-89 years) with mild or moderate hypertension (systolic blood pressure 160-179 mmHg and/or diastolic blood pressure 90-99 mmHg). [16] [17] [18] [19] [20] However, because of changes in treatment guidelines and for ethical reasons, it was decided during the recruitment period to recommend additional open-label active antihypertensive treatment in both treatment groups for patients whose blood pressure remained high. The study therefore actually compared candesartan-based treatment with usual antihypertensive treatment not including candesartan. The rationale for using candesartan is provided in Hansson et al. 18 The use of different types of antihypertensive treatments during the study is described in Lithell et al. 20 Health-related quality of life (HRQL) and resource utilization were assessed in a subsample of the study population.
The objective of this study was to assess the cost-effectiveness of nonfatal stroke prevention with candesartan-based antihypertensive treatment compared with usual antihypertensive treatment not including candesartan, based on results from SCOPE.
Methods and materials
The cost-effectiveness analysis was carried out using a Markov model constructed in the decisionanalytic program package DATA (TreeAge Software Inc). The model predicted costs and qualityadjusted life years (QALYs) over the remaining lifetime of the patients (limited to 110 years of age). The average follow-up time in SCOPE was 3.7 years. Patients in the candesartan group were therefore assumed to be treated with candesartan for a maximum of 4 years. Treatment cost, risk of nonfatal stroke, mortality during the first 4 years, cost of nonfatal stroke and utility reduction from nonfatal stroke were based on data collected in SCOPE. Epidemiological data were used to estimate mortality after the follow-up of the study. The analysis focused exclusively on the effects of candesartanbased antihypertensive treatment on the risk of prevention of nonfatal stroke since there were no significant differences in other cardiovascular events. 20 
Costing
Resource utilization data recorded in SCOPE were multiplied by Swedish unit costs, converted into the 2001 price level using the general consumer price index. 21 The costs were then converted into euros by using the average exchange rate between Swedish crowns and euros in 2001 (9.25 SEK/EUR). 22 The perspective of the cost-effectiveness analysis was that of society. Costs and outcomes were discounted at a real rate of 3%. 23 The Markov model structure In a Markov model, it is assumed that disease progression can be described by a finite number of health states. 24 Each health state is associated with a certain cost and a health state utility. Patients may transit from one health state to another during a defined interval of time called a cycle. In this analysis, transitions between health states were assumed to occur at yearly intervals. The structure of the Markov model is presented in Figure 1 . There Figure 1 Structure of the Markov model. are two arms in the model: candesartan-based treatment and usual antihypertensive treatment. In both arms, there are four possible health states. In each one-year cycle, the patient stays healthy, suffers an acute stroke, lives with a previous stroke (post stroke), or dies.
Risk of nonfatal stroke
The risk of nonfatal stroke was based on the risks observed in SCOPE. A first nonfatal stroke occurred in 68 patients in the candesartan group (7.4 events per 1000 patient-years) and in 93 patients in the control group (10.3 events per 1000 patient-years), a risk reduction of 27.8% (95% confidence interval (CI), 1.3-47.2, P ¼ 0.04). 20 The total number of nonfatal strokes in SCOPE was 72 in the candesartan group and 106 in the control group (data on file). The mechanisms of action of candesartan in preventing nonfatal stroke have been discussed in Lithell et al. 20 The probability of a new nonfatal stroke was based on the total number of nonfatal strokes per year of follow-up in SCOPE. The same annual risks were used for each of the first four years. Nonfatal strokes occurring after the first 4 years were not included in the model, since the effect of antihypertensive treatment given during year 5 and onwards is not known.
Cost of nonfatal stroke
The cost of nonfatal stroke was estimated using resource utilization data recorded in a total of 2990 patients in seven countries in SCOPE (Canada, France, Germany, The Netherlands, Sweden, UK, USA). The data were divided into the following categories: concomitant medication, living arrangements, hospitalizations, hospital procedures, and unscheduled health care visits. All direct medical and community care (e.g. special accommodation) costs were included. Since all patients were over 70 years of age, there were no indirect costs for productivity losses due to disease.
Concomitant medications in SCOPE were classified according to the fourth level of the Anatomical Therapeutic Chemical (ATC) classification system, which groups together drugs with similar therapeutic effect and mode of action. Concomitant medications with less than 20 prescriptions were assumed to have a minimal impact on the total cost and were therefore excluded from the analysis. Costs for concomitant medications were calculated using Swedish retail prices. 25 Living arrangements were divided into the following categories: old age/residential home, block of service flats/sheltered housing, group living, nursing home, geriatric psychiatric care or long-term hospital care. Daily unit costs for each category were obtained from county councils in Sweden and published sources. 26, 27 The costing of in-patient care was based on the number of days spent in different types of hospital wards, the number of surgical and diagnostic procedures and unit costs at Swedish hospitals. 26, 28 The cost of unscheduled visits to general practitioner, nurse, specialized physician, hospital outpatient clinic, day hospital centre and rehabilitation was calculated using unit costs obtained from county councils in Sweden. 28 The stroke-related cost during the first year after the event was calculated as the difference between the cost 1 year before and after stroke, using individual patient data for those who had a followup time of at least 1 year before and after the event. The stroke-related cost for the second year and onwards was calculated by first dividing the average cost during the second year and onwards by the average follow-up time during the second year and onwards and then subtracting the average cost 1 year before stroke. (Alternatively, the cost per year during the second year and onwards could have been calculated using individual patient data. This, however, would have generated uncertain cost estimates for patients with very short follow-up time.) Only the stroke-related costs were used in the model; thus, costs the year before stroke were not included.
Cost of antihypertensive treatment
Cost of antihypertensive treatment was based on the number of treatment days in SCOPE and Swedish retail prices. 25 
Cost in added years of life
When an intervention extends life expectancy, additional health care and non-health care costs will be incurred during the added years of life. According to Meltzer, 29 these costs should be included in a cost-effectiveness analysis conducted from the societal perspective. Costs in added years of life can be calculated as the difference between annual production and consumption in different age groups. 29, 30 Costs in added years of life in the general Swedish population were included in the sensitivity analysis. 31 
Outcome measure
The primary outcome measure in the cost-effectiveness analysis was the number of QALYs, which were obtained by multiplying life-years by health statespecific utilities. The utilities were estimated using the EQ-5D instrument, which was administered in a total of 2850 patients in six countries in SCOPE (France, Germany, The Netherlands, Sweden, UK, USA). The EQ-5D health state descriptions were converted into utilities using population weights for the UK. 32 
Mortality
For patients without nonfatal stroke, mortality during the first 4 years was taken from SCOPE, where the average total mortality was 2.85% per patient-year. 20 This mortality rate was used for all patients without nonfatal stroke in both treatment groups and included death due to fatal stroke and other causes. After the first 4 years, mortality for patients without stroke was based on the mortality in the general age-and sex-matched population in Sweden. 33 Mortality in patients with a previous stroke was based on data from the national Swedish Inpatient Registry. A sample of approximately 52 000 patients, aged above 75 years, hospitalized with a diagnosis of stroke and who had survived the first 28 days after the stroke was obtained. Data were available for the first 3 years after the onset of stroke. The age-specific relative mortality shown in Table 1 was calculated from the average relative mortality during the first, second and third year after stroke at each age, compared to the aged-matched mortality in the general population. The first-year relative mortality was used for the first year after stroke. For the following years, the average of the second-and third-year relative mortality at each age was used. Studies have shown that the increase in relative mortality during the second and third year after a stroke is sustained for a long time after a stroke, which implies that the rather slow decrease in relative mortality with time in Table 1 is probably a realistic modelling assumption. 34 
Sensitivity analysis
The sensitivity of the base-case results to changes in key parameter values in the model was analysed with regard to variation in annual antihypertensive treatment cost (upper and lower limit of the 95% CI for the difference between treatment groups), firstyear stroke cost (upper and lower 95% CI limit), second-year stroke cost, stroke risk, first-and second-year utilities, mortality risks and discount rate. For the second-year stroke cost, there was no CI since the cost was calculated using average data rather than individual patient data. Instead upper and lower values in the sensitivity analysis were obtained by multiplying the second-year cost by the CI limits for the first-year cost divided by the firstyear cost. (The underlying assumption is that the second-year costs should have about the same relative variability as the first-year cost.) Upper and lower values for utilities were based on the assumption that stroke does not increase utility on average; the lower value for the utility the year before stroke was equal to the highest utility the first or second year after stroke. Also, the upper value for the utility the first and second year after stroke was equal to the utility before stroke. The upper value for the utility before stroke and the lower values for the utilities for the first and second year after stroke were obtained by constructing a symmetrical interval around the base-case utilities. The discount rate was varied between 0 and 5%, and the same discount rate was applied to both costs and health effects. For other parameters, we used what we felt would be reasonable ranges for upper and lower values, for example, 730%.
Results

Costs
The average cost during 1 year before and after nonfatal stroke was 5510 EUR and 14 717 EUR, respectively ( Table 2 ). The difference of 9206 EUR is an estimate of the stroke-related cost during the first year after the event. For the second year and onwards, the average cost per year was 9850 EUR. Subtracting the cost during the year before stroke gives a stroke-related cost of 4340 EUR per year for the second year and onwards. We did not include the costs for patients who had a follow-up time shorter than 1 year, since these costs were not comparable to the one-year costs. However, the cost per day was similar to that for patients with a follow-up time longer than 1 year (35 and 40 EUR, respectively).
Utilities
The average utility during 1 year before stroke was 0.77, calculated as the average utility in patients with a follow-up time longer and shorter than 1 year (0.80 and 0.72, respectively), weighted according to the number of patients in these two groups. During the first year after stroke, the weighted average utility was 0.70 (0.75 and 0.61 in patients with a follow-up time longer and shorter than 1 year, respectively). The utility for the second year was used also for subsequent years, but we took account of the aging of the population by using the agespecific relative decline by age in HRQL reported by Lundberg. 35 
Costs, health effects and cost-effectiveness ratios
The cost per patient was 1949 EUR in the candesartan group and 1578 EUR in the control group (Table 3 ). The largest share of the cost was attributed to antihypertensive treatment in the candesartan group and to the long-term cost of stroke in the control group. About half of the higher cost of antihypertensive treatment in the candesartan group was offset by lower costs for treating stroke, resulting in a net cost of 371 EUR per patient. The long-term cost of stroke contributed to the largest share of the cost offset.
Fewer nonfatal strokes also led to avoided premature deaths and increased quality-adjusted life expectancy; candesartan-based antihypertensive treatment was associated with 0.0434 additional life years and 0.0289 additional QALYs per patient (Table 4) . Combining this gain in QALYs with the cost difference of 371 EUR per patient gives an incremental cost per QALY gained of approximately 13 000 EUR. There were 14.5 fewer nonfatal strokes per 1000 treated patients in the candesartan group, yielding an incremental cost per nonfatal stroke prevented of approximately 26 000 EUR (371/ 0.0145).
Sensitivity analysis
The sensitivity analyses showed that the base-case results were fairly stable ( Table 5 ). Risk of stroke and stroke cost during the second year and onwards were the most important parameters for the costeffectiveness ratio. As expected, the cost-effectiveness ratio increased when costs in added years of life were included.
Discussion
This study assessed costs and effects of nonfatal stroke prevention with candesartan-based antihypertensive treatment in elderly patients with mild to moderate hypertension, based on results from the large randomized clinical study SCOPE (Table 6 ). The results demonstrated that about half of the higher cost of antihypertensive treatment in the candesartan group was offset by lower costs for treating strokes, resulting in a net cost of 371 EUR per patient. Candesartan-based antihypertensive treatment was associated with 0.0289 additional QALYs per patient and an incremental cost per QALY gained of approximately 13 000 EUR.
Threshold value for the cost-effectiveness ratio
Even if there is no formal threshold for the costeffectiveness ratio, 13 000 EUR per QALY gained must be considered as very favourable. 36, 37 Different methods for estimating willingness to pay for a QALY result in widely varying results, from a median of 25 000 USD per QALY for estimates based on human capital methods to a median of 428 000 USD for estimates based on wage premiums for job risks. 37 Based on the willingness to pay for saving lives used in evaluations of investments in road safety in Sweden, a willingness to pay per QALY of 66 000 EUR can be calculated for 2001. 38, 39 This may be an appropriate threshold value against which the Cost-effectiveness of candesartan-based antihypertensive treatment J Lundkvist et al cost per QALY gained in this study can be assessed. However, as Johannesson 15 has pointed out the societal willingness to pay per QALY gained may differ between the prevention of cardiovascular disease and the prevention of road accidents. In any case, all cost-effectiveness ratios in the sensitivity analysis were below the threshold value of 66 000 EUR per QALY, which indicates that prevention of non-fatal stroke with candesartan-based antihypertensive treatment is cost-effective.
Comparison of costs and utilities in SCOPE and previous studies
The stroke cost during the first year after the event was 9206 EUR, which is lower than cost estimates from other Swedish cost-of-illness studies of stroke. The direct stroke-related cost during the first year after stroke was approximately 11 000 EUR in Zethraeus et al, 40 18 000 EUR in Claesson et al 41 and 17 000 EUR in Gatnekar et al. 42 The difference is probably explained by the fact that the SCOPE population was selected based on a number of inclusion and exclusion criteria and thus healthier than an age-matched sample of the general population. This hypothesis is supported by the fact that the SCOPE population actually had a lower average mortality than the general Swedish population of the same age. For the second year and onwards, SCOPE gave a stroke-related cost of 4340 EUR, while Ghatnekar et al 42 found a cost of about 6000 EUR for years 2-4 after a first stroke. The findings of Ghatnekar et al support our assumption that the second-year cost may be extrapolated to subsequent years.
The average utility during 1 year before stroke was 0.77, which is in line with utilities in age-matched samples of the general Swedish population; A favourable design for evaluating the costeffectiveness SCOPE was initiated as a placebo-controlled study. However, because of changes in treatment guidelines and for ethical reasons, it was decided during the recruitment period to recommend additional open-label active antihypertensive treatment in both treatment groups for patients whose blood pressure remained high. The study therefore compared candesartan-based treatment with usual antihypertensive treatment not including candesartan. Even if this meant that the study did not have enough statistical power to detect a statistically significant difference between the treatment groups for most cardiovascular events, the design was an advantage from a health economic viewpoint, since placebo is not an appropriate comparator for the majority of patients with mildly to moderately elevated blood pressure. Costs and health effects of a particular treatment should instead be compared with the most appropriate alternative, that is, current standard treatment for the condition in question.
There are other aspects that made SCOPE fairly naturalistic. It had a relatively long follow-up time, and the patient population was representative in terms of age and gender; patients in clinical studies are often younger than the average patient in clinical practice, and men tend to be overrepresented. Not so in SCOPE, however, where the average age was 76 years and nearly two-thirds of the patients were women. Thus, SCOPE lent itself well to a realistic cost-effectiveness analysis of nonfatal stroke prevention with candesartan-based antihypertensive treatment.
As a result of patient selection by inclusion and exclusion criteria, and close monitoring, the event rates in clinical studies are often lower than those achieved in clinical practice, where the conditions are less ideal. That may explain why mortality in SCOPE was lower than in an age-and gendermatched sample of the general population. The stroke costs were also lower than those reported for population-based samples, in particular for the first year after the event. Higher stroke costs in our analysis would have implied an even more favourable cost-effectiveness ratio since more would then be gained by preventing stroke.
If stroke costs and mortality had been higher and the baseline utility lower in SCOPE than in age-and gender-matched samples of the general population, this would have indicated that the SCOPE population was a high-risk population not necessarily representative of the average patient. This in turn could have led to an overestimation of the costeffectiveness of candesartan-based antihypertensive treatment, since prevention is typically more costeffective in high-risk groups. 15 If anything, however, the SCOPE population was healthier and had lower stroke costs than population-based samples, which means that such an overestimation is unlikely.
Data from several countries
Resource utilization and EQ-5D data were aggregated across the countries that participated in the substudies. Aggregating resource utilization may be problematic since treatment patterns and relative prices may vary from country to country. Analysing data only from Sweden or the Nordic countries, however, would have led to a much smaller patient sample, which in turn would have led to more uncertain estimates of costs and health effects.
As mentioned above, the price level for medical services varies between countries. However, firstyear costs for stroke are similar in Sweden, Denmark, France, Germany and the Netherlands, 44 which makes it reasonable to assume that the results of this cost-effectiveness analysis are valid for at least Northern and Western European countries.
Conclusion
The cost per QALY gained with candesartan-based antihypertensive treatment lies within the range of society's willingness to pay for health gains. The results indicate that candesartan-based antihypertensive treatment is cost-effective for the prevention of nonfatal stroke.
